Appointment dossier — Melanoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Melanoma
No studies or cited compounds on file for this cancer yet.
Open recruiting trials (18)
- NCT03567889 · Phase 3 — Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (United States)
- NCT05549297 · Phase 3 — Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) (United States)
- NCT05296564 · Phase 1 / Phase 2 — Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers (Israel)
- NCT07063875 · Phase 1 / Phase 2 — Adding IL-2 to Tebentafusp to Eradicate Cancer Progression (Australia)
- NCT06727630 · Phase 1 / Phase 2 — A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma (China)
- NCT04114136 · Phase 2 — Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies (United States)
- NCT05546827 · Phase 2 — Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma (United States)
- NCT02621021 · Phase 2 — A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab (United States)
- NCT07410676 · Phase 1 / Phase 2 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (China)
- NCT07070518 · Phase 1 / Phase 2 — Study of GV20-0251 in Participants With Solid Tumor Malignancies (China)
- NCT04903119 · Phase 1 — Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma (United States)
- NCT04282044 · Phase 1 — Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies (United States)
- NCT03116412 — A Randomized Trial to Assess the Role of Imaging During Follow Up After Radical Surgery of High Risk Melanoma (Sweden)
- NCT07318051 — Sample Collection for Ongoing Research and Product Evaluation Study (United States)
- NCT06970236 — Resistance Exercise in Patients With Ocular Melanoma (Spain)
- NCT06627595 — Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management (France)
- NCT07223411 — Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma (United States)
- NCT07201376 — Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically (United States)
Most-relevant first: trials that name Melanoma, then broader trials you may still qualify for. 477 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Questions to ask your oncologist
- Of the open trials I found (for example NCT03567889), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?